FSD Pharma has submitted a Clinical Trial Application (CTA) for a Phase-1b study, the METAL-1 TRIAL, to evaluate the safety and efficacy of its dietary supplement, unbuzzd™.

Delta-Fly Pharma has recently completed the submission of a Phase I/II clinical trial protocol for a combination therapy involving their drug DFP-10917 and Venetoclax (VTX).

Syena, a subsidiary of Replay specializing in cell therapy, has initiated a Phase 1/2 clinical trial for patients with multiple myeloma.

Immuneering Corporation has commenced the Phase 2a segment of its Phase 1/2a clinical trial for IMM-1-104.

Plus Therapeutics has successfully dosed 18 patients in the ReSPECT-LM Phase 1 trial, which focuses on the treatment of leptomeningeal metastases (LM) from solid tumors using rhenium (186Re) obisbemeda.

The Data Safety Monitoring Board (DSMB) has reviewed the safety of SON-080 in the Phase 1b part of Sonnet's clinical trial.

Nurix Therapeutics has received a boost as the FDA lifted a partial clinical hold on their Phase 1a/1b study of NX-2127.

Synnovation Therapeutics has announced the commencement of dosing for the first patient in their Phase I clinical trial of SNV1521, a PARP1 inhibitor, in patients with solid tumors.

Imugene Limited has announced the successful completion of the initial phase of its OASIS clinical trial.

Eilean Therapeutics LLC announced that its Australian subsidiary has received approval from the Human Research Ethics Committee to begin a Phase 1 clinical trial of balamenib (ZE63-0302).

Regulus Therapeutics has reported promising outcomes from the second group of participants in a Phase 1b clinical trial for a new drug, RGLS8429.

The trial is assessing the efficacy of KVA12123, a VISTA-blocking immunotherapy, both as a standalone treatment and in conjunction with Merck’s KEYTRUDA® (pembrolizumab).